TCGA-DK-A1AB-01A-11R-A13Y-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 16.68856767
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- INTERFERON_ALPHA_RESPONSE+0.530
- HEDGEHOG_SIGNALING+0.490
- INTERFERON_GAMMA_RESPONSE+0.490
- UV_RESPONSE_DN+0.440
- ANDROGEN_RESPONSE+0.400
- ANGIOGENESIS+0.390
- COMPLEMENT+0.340
- TGF_BETA_SIGNALING+0.340
- PROTEIN_SECRETION+0.330
Top 10 suppressed
- MYC_TARGETS_V2-0.470
- E2F_TARGETS-0.420
- DNA_REPAIR-0.400
- OXIDATIVE_PHOSPHORYLATION-0.280
- MYC_TARGETS_V1-0.250
- SPERMATOGENESIS-0.180
- CHOLESTEROL_HOMEOSTASIS-0.100
- UV_RESPONSE_UP-0.100
- ADIPOGENESIS-0.090
- G2M_CHECKPOINT-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A24V-01A-21R-A169-07 | — | A | 0.899 |
| 2 | TCGA-DK-A1AF-01A-11R-A13Y-07 | — | — | 0.898 |
| 3 | TCGA-CR-7386-01A-11R-2016-07 | — | — | 0.891 |
| 4 | efe57fc7-7cf4-432b-86ff-9fd2d1a37b5e | — | — | 0.876 |
| 5 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.872 |
| 6 | TCGA-44-6777-01A-11R-1858-07 | — | cohortA1 | 0.871 |
| 7 | TCGA-CV-7104-01A-11R-2016-07 | — | — | 0.868 |
| 8 | TCGA-CR-7394-01A-11R-2016-07 | — | — | 0.866 |
| 9 | TCGA-86-8055-01A-11R-2241-07 | — | cohortA1 | 0.859 |
| 10 | ERR2208918 | — | — | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.490 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.440 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.290 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |